#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Oesophageal adenocarcinoma stage III White matter lesion Staphylococcal infection Malignant melanoma Gastrointestinal neuroendocrine tumour Ewing's sarcoma recurrent Fabry's disease Penile squamous cell carcinoma SAPHO syndrome Polyneuropathy Asthma Blastic plasmacytoid dendritic cell neoplasia Erythema multiforme Mantle cell lymphoma recurrent Complex regional pain syndrome More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis I – Diagnostics Atypical haemolytic uraemic syndrome Activated PI3 kinase delta syndrome – Life with Disease Breast angiosarcoma – Life with Disease Myelodysplastic syndrome – Life with Disease Alport’s syndrome – Life with Disease Von Willebrand’s disease – Treatment Mantle cell lymphoma refractory – Life with Disease Von Willebrand’s disease – Diagnostics Haemophilia More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Eculizumab Mycophenolate Mofetil Dapagliflozin Propanediol Omx-0407 POLYMYXIN B SULFATE Rilpivirine Hydrochloride Rasagiline Dexibuprofen Diltiazem Hydrochloride Dimethyl Fumarate HYDROMORPHONE HYDROCHLORIDE Venetoclax Vonicog Alfa Cobolimab Bupivacaine Hydrochloride Secale Cereale Paracetamol Dc Ertapenem Sodium Marstacimab Talquetamab More therapies…

    Learn about Your Condition

    PIK3CA-activated mutation Cholecystitis acute Labour pain Procedural haemorrhage Stress Plasma cell leukaemia Prodromal Alzheimer's disease Mucopolysaccharidosis III Chronic granulomatous disease Mixed dementia Immunodeficiency congenital Progressive multiple sclerosis Skin bacterial infection Aortic stenosis Metastasis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Fakultni Nemocnice Plzen

Fakultni Nemocnice Plzen

Edvarda Benese 1128/13, Jizni Predmesti, Plzen, 301 00, Czechia

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

    Recruiting

    3 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Selatogrel
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Long‑Term Follow‑Up Study of Belzupacap Sarotalocan in Patients with Early Choroidal Melanoma

    Not yet recruiting

    3 1
    Investigated Drugs:
    • Belzupacap Sarotalocan
    Austria Belgium Czechia France Germany Italy +2

  • Clinical Trial of Human Normal Immunoglobulin to Prevent Infections in Patients with Secondary Antibody Deficiency due to CLL, Multiple Myeloma or Non‑Hodgkin Lymphoma

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    • Plasma cell myeloma
    • Non-Hodgkin’s lymphoma
    Investigated Drugs:
    • Human Normal Immunoglobulin
    Czechia France Italy Poland Spain

  • Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    • Bortezomib
    • Daratumumab
    Czechia France Germany Greece Italy The Netherlands +3

  • A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

    Not yet recruiting

    4 1 1
    Investigated Drugs:
    • Inebilizumab
    Belgium Bulgaria Czechia France Germany Greece +6

  • Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Idarubicin Hydrochloride
    • Inotuzumab Ozogamicin
    • Tioguanine
    Austria Czechia Denmark Finland France Germany +6

  • Study on Vitamin D3 (Colecalciferol) Supplementation in Young Adults and Seniors to Develop Age-Specific Models for Healthy Individuals

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Colecalciferol
    Czechia

  • Study on Allogeneic Faecal Microbiota for Treating Antibiotic-Related Diarrhea in Critically Ill Patients

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Diarrhoea
    Investigated Drugs:
    • Allogeneic Faecal Microbiota, Pooled
    Czechia

  • Study of Brentuximab Vedotin with Drug Combination for Untreated CD30-expressing Peripheral T-cell Lymphoma Patients

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Brentuximab Vedotin
    • Cyclophosphamide
    • Doxorubicin
    Czechia

  • Study of Avacopan Safety and Effectiveness in Patients with ANCA-associated Vasculitis

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Anti-neutrophil cytoplasmic antibody positive vasculitis
    Investigated Drugs:
    • Avacopan
    • Azathioprine
    • Cyclophosphamide
    Czechia Denmark France Greece Hungary Poland +1
Previous Page
1 2 3 4 5 6 … 10
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!